LONDON, May 14, 2015 /PRNewswire/ --
Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful $275 million Nasdaq IPO for Galapagos NV, a major European clinical-stage biotechnology company. Bryan, Garnier & Co is the only European investment bank in the IPO syndicate. The Galapagos IPO on Nasdaq confirms the strong momentum of the European healthcare sector.
Galapagos NV (Euronext: GLPG) announced today the pricing of its global offering totaling $275 million gross proceeds, initially filed for $150 million. The new shares were placed in a concurrent public offering in the US through ADSs at a price of $42.05 and private placement in Europe at a price of €37 per share. It is the largest Nasdaq IPO of a European biotech and one of three largest biotech IPO ever in Europe or in the US.
Bryan, Garnier & Co acted as co-manager and sole European investment bank, alongside Morgan Stanley, Credit Suisse, Cowen and Company and Nomura.
Bryan Garnier & Co keeps on leading the financing of the European healthcare companies, in Europe and in the US:
- Bryan, Garnier & Co was the only European investment bank involved in the top 5 IPOs of European healthcare companies on Nasdaq i.e. Galapagos (Belgium), DBV Technology (France), Forward Pharma (Denmark), Cellectis (France), Adaptimune (UK), as well as in the IPO of LDR Holding (US/France).
- Bryan, Garnier & Co confirms its leading position in the financing of the European emerging biopharma industry, through private equity placements, PIPEs, and public offerings, on both the European and the American equity capital markets (LSE, AIM, Euronext, Alternext, and Nasdaq OMX).
- Cumulated placements managed by Bryan, Garnier & Co in healthcare exceeded 1b€ over the past 24 months including 3 Nasdaq IPOs (Galapagos, DBV Technologies and LDR Holding).
About Galapagos: http://www.glpg.com
About Bryan, Garnier & Co: http://www.bryangarnier.com
SOURCE Bryan, Garnier & Co